BIRC5 and diffuse large B-cell lymphoma: Our findings also suggest that further studies are needed to examine the feasibility of using survivin as a therapeutic target in DLBCL patients with the subtypes having higher risk of relapsed or refractory disease, such as ABC subtype DLBCL and EBV-positive DLBCL of the elderly.